Devimistat is under clinical development by Cornerstone Pharmaceuticals and currently in Phase II for Sarcomas. According to GlobalData, Phase II drugs for Sarcomas have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Devimistat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Devimistat overview

Devimistat (CPI-613) is under development for the treatment of Burkitt lymphoma or High-grade B-cell Lymphoma, metastatic pancreatic cancer, metastatic colorectal cancer, gallbladder cholangiocarcinoma, extrahepatic cholangiocarcinoma, intrahepatic cholangiocarcinoma as first line of therapy, metastatic biliary tract cancer, hematologic malignancies including relapsed or refractory myelodysplastic syndrome, soft tissue sarcoma, ewing sarcoma, relapsed or refractory granulocytic sarcoma, peripheral T-cell lymphoma, relapsed or refractory T-cell Hodgkin lymphoma, T-cell non-Hodgkin lymphoma. It is administered as an intravenous infusion. CPI-613 is an analogue of alpha-lipoic acid that targets the mitochondrial enzymes pyruvate dehydrogenase (PDH) and alpha-ketoglutarate dehydrogenase. The drug candidate is based on altered energy metabolism directed (AEMD) drug platform. It was also under development for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma, pancreatic ductal adenocarcinoma, non-small cell lung cancer and solid tumors. It was under development for extrahepatic cholangiocarcinoma, intrahepatic cholangiocarcinoma,  and metastatic cholangiocarcinoma (bile duct cancer), relapsed or refractory acute myelocytic leukemia (AML) as second line of therapy, and pancreatic ductal adenocarcinoma as first line therapy.

Cornerstone Pharmaceuticals overview

Cornerstone Pharmaceuticals, formerly Rafael Pharmaceuticals, is a metabolic oncology therapeutics company. It develops and commercializes cancer metabolic drugs. The company focuses on investigating CPI-613 (Devimistat), an anti-mitochondrial drug in combination with other drug medicines such as mfolfirinox, folfox, bevacizumab and hydroxychloroquine for the treatment of pancreatic and colorectal cancer; acute myeloid leukemia (AML), Myelodysplastic syndromes (MDS), peripheral T-cell lymphoma and Burkitt’s lymphoma. It utilizes an altered metabolism-directed (AMD) platform to split biochemical alterations and develop drugs. The company collaborates with researchers, companies and universities to produce medicines. Cornerstone Pharmaceuticals is headquartered in Cranbury, New Jersey, the US.

For a complete picture of Devimistat’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.